Imatinib in gastrointestinal stromal tumor: Does treatment duration matter?

Oncology

Volumn 77, Issue 3-4, 2009, Pages 157-161

  Adenis, Antoine ^a,b,c   Penel, Nicolas ^a,c   Blay, Jean Yves ^c,d  

^a CENTRE OSCAR LAMBRET   (France)

^b Catholic University   (France)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Adjuvant treatment; Gastrointestinal stromal tumor; Imatinib; Treatment duration; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB;

CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES; TIME FACTORS;

EID: 69549107439     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236019     Document Type: Review

References (28)

1. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
2. Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-1741.
3. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol 2002; 33: 459-465. (Pubitemid 34747864)
4. Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
5. DeMatteo RP, Gold, JS, Saran L, Gönen M, Liau, KH, Maki, RG, Singer S, Besmer P, Brennan MF, Antonescu CR: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary Gastrointestinal Stromal Tumor. Cancer 2008; 112: 608-615.
6. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA , Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
7. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Schlemmer M, van Glabbeke M, Brown M, Judson IR: Progression- free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
8. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. (Pubitemid 351264358)
9. van Glabbeke M, Owzar K, Rankin C, Simes J, Crowley J: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis based on 1,640 patients (abstract). J Clin Oncol 2007; 25: 10004.
10. DeMatteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, Blanke C, Demetri G, von Mehren M, Ballman K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor: North American Intergroup Phase III trial ACOSOG Z9001 (abstract). J Clin Oncol 2007; 25: 10079.
11. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PWT, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
12. Blay JY, Le Cesne A, Ray-Coquard I, Bui BN, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.
13. Rios M, Le Cesne A, Bui BN, Adenis A, Bertucci F, Duffaud F, Emile JF, Chabaud S, Pérol D, Blay JY, French Sarcoma Group: Interruption of imatinib in GIST patients with advanced disease after one year of treatment: updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival (abstract). J Clin Oncol 2007; 25: 10016.
14. Le Cesne A, Ray-Coquard I, Bui BN, Rio M, Adenis A, Viens P, Duffaud F, Bourne- Branchu V, Perol D, Blay JY, French Sarcoma Group: Continuous vs. intermittent imatinib treatment in advanced GIST after three years: a prospective randomized phase III trial of the French Sarcoma Group (abstract). J Clin Oncol 2007; 25: 10005.
15. Adenis A, Cassier P, Bui BN, Rios M, Duffaud F, Bertucci F, Chabaud S, Perol D, Blay Jy, Le Cesne A, French Sarcoma Group: Does interruption of imatinib in responding patients after three years of treatment: influence outcome of patients with advanced GIST included in the BFR14 trial? (abstract). J Clin Oncol 2008; 26: 10522.
16. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY: Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19:ii35-ii38.
17. Stoeckle E, Meeus P, Rios M, Duffaud F, Bertucci F, Adenis A, Chabaud S, Blay JY, Le Cesne A, Bonvalot S, French Sarcoma Group: Complete resection of residual disease in responding patients to imatinib positively influences the outcome of patients with advanced GIST: the experience of the BFR14 trial of the French Sarcoma Group. (abstract). J Clin Oncol 2008; 26: 10549.
18. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG: Surgery of residual disease following molecular- targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341-346.
19. Bui BN, Le Cesne A, Ray-Coquard I, Duffaud F, Rios M, Adenis A, Bompas E, Perol D, Berthaud P, Blay JY: Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial (abstract). J Clin Oncol 2008; 24: 9501.
20. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, van Glabbeke M, Brown M, Judson IR, EORTC Bone Tissue and Sarcoma Group, the Italian Sarcoma Group, Australasian Gastrointestinal trials Group: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
21. National Comprehensive Cancer Network: www.nccn.org/professionals/ physician-gls/PDF/sarcoma.pdf.
22. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CDM, Demetri GD, Bertagnolli MM: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331.
23. van den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, Armand M, Baum C, Demetri GD: Effects of cessation of imatinib mesylate (IM) therapy in patients with IM-refractory gastrointestinal stromal tumors as visualized by FDG-PET scanning (abstract). J Clin Oncol 2004; 22: 3012.
24. US National Institutes of Health Clinical Trials: Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. www.clinicaltrials.gov/ct/ show/NCT00103168.
25. US National Institutes of Health Clinical Trials: Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). www.clinicaltrials.gov/ct/show/NCT00116935.
26. Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y, Nishida T: An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 2007; 12: 369-374.
27. Tryggvason G, Gislason HG, Magnusson MK, Jönasson JG: Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.
28. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/ recurrent operable gastrointestinal stromal tumor: early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-47.